Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS: ODM-111 in Chronic Knee Osteoarthritis Pain
2024-513553-79-00Phase 2Completed
- Sponsor
- Orion Corporation
- Start
- Oct 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of JMKX000623 in knee osteoarthritis (OA) (3 arms), sponsored by Orion Corporation. Primary endpoint: Change from baseline to week 6 in WOMAC pain subscale. Started Oct 2024; status: completed.
02
Drugs
JMKX000623
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on 2024-513553-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513553-79-00.